Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 3—March 2016
Online Report

Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis

Jennifer FurinComments to Author , Grania Brigden, Erica Lessem, Michael Rich, Laura Vaughan, and Sharonann Lynch
Author affiliations: Harvard Medical School, Boston, Massachusettes, USA (J. Furin); Médecins Sans Frontières Access Campaign, Geneva, Switzerland (G. Brigden, S. Lynch); Treatment Action Group, New York, NY, USA (E. Lessem); Brigham and Women’s Hospital, Boston (M. Rich); Partners In Health, Boston (M. Rich, L. Vaughan)

Main Article

Table 4

World Health Organization–defined high-burden, low- and middle-income countries using or waiting for drug arrival to begin using bedaquiline under program conditions for treatment of multidrug-resistant tuberculosis

Currently using Awaiting drug arrival
Armenia Bangladesh
Belarus Bolivia
Georgia Brazil
Indonesia Cameroon
Lesotho Cote d’Ivoire
Papua New Guinea North Korea
Russia Democratic Republic of the Congo
South Africa Ethiopia
Swaziland India
Kazakhstan
Kenya
Kyrgyzstan
Mozambique
Myanmar
Namibia
Nigeria
Peru
Philippines
South Korea
Thailand
Turkmenistan
United Republic of Tanzania
Uzbekistan
Vietnam

Main Article

Page created: February 18, 2016
Page updated: February 18, 2016
Page reviewed: February 18, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external